Geode Capital Management’s Voyager Therapeutics VYGR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $4.66M | Buy |
1,330,492
+280,514
| +27% | +$1.06M | ﹤0.01% | 2957 |
|
|
2026
Q1 | $4.05M | Sell |
1,049,978
-85,210
| -8% | -$335K | ﹤0.01% | 2848 |
|
|
2025
Q4 | $4.46M | Sell |
1,135,188
-13,424
| -1% | -$59.4K | ﹤0.01% | 2843 |
|
|
2025
Q3 | $5.36M | Buy |
1,148,612
+31,765
| +3% | +$115K | ﹤0.01% | 2742 |
|
|
2025
Q2 | $3.47M | Buy |
1,116,847
+11,929
| +1% | +$38.5K | ﹤0.01% | 2912 |
|
|
2025
Q1 | $3.74M | Buy |
1,104,918
+20,680
| +2% | +$96.6K | ﹤0.01% | 2800 |
|
|
2024
Q4 | $6.15M | Buy |
1,084,238
+4,729
| +0.4% | +$30.5K | ﹤0.01% | 2640 |
|
|
2024
Q3 | $6.32M | Buy |
1,079,509
+6,740
| +0.6% | +$49K | ﹤0.01% | 2638 |
|
|
2024
Q2 | $8.49M | Buy |
1,072,769
+100,405
| +10% | +$842K | ﹤0.01% | 2421 |
|
|
2024
Q1 | $9.05M | Buy |
972,364
+293,486
| +43% | +$2.48M | ﹤0.01% | 2382 |
|
|
2023
Q4 | $5.73M | Buy |
678,878
+31,933
| +5% | +$232K | ﹤0.01% | 2634 |
|
|
2023
Q3 | $5.01M | Buy |
646,945
+56,690
| +10% | +$518K | ﹤0.01% | 2639 |
|
|
2023
Q2 | $6.76M | Buy |
590,255
+317,000
| +116% | +$3.28M | ﹤0.01% | 2533 |
|
|
2023
Q1 | $2.11M | Buy |
273,255
+517
| +0.2% | +$4.11K | ﹤0.01% | 3000 |
|
|
2022
Q4 | $1.66M | Buy |
272,738
+1,716
| +0.6% | +$9.75K | ﹤0.01% | 3127 |
|
|
2022
Q3 | $1.6M | Buy |
271,022
+300
| +0.1% | +$1.92K | ﹤0.01% | 3161 |
|
|
2022
Q2 | $1.6M | Buy |
270,722
+7,025
| +3% | +$47.5K | ﹤0.01% | 3197 |
|
|
2022
Q1 | $2.01M | Sell |
263,697
-88,267
| -25% | -$394K | ﹤0.01% | 3253 |
|
|
2021
Q4 | $953K | Buy |
351,964
+73,318
| +26% | +$250K | ﹤0.01% | 3746 |
|
|
2021
Q3 | $732K | Buy |
278,646
+520
| +0.2% | +$1.69K | ﹤0.01% | 3842 |
|
|
2021
Q2 | $1.15M | Sell |
278,126
-186,692
| -40% | -$846K | ﹤0.01% | 3519 |
|
|
2021
Q1 | $2.19M | Buy |
464,818
+73,162
| +19% | +$499K | ﹤0.01% | 3217 |
|
|
2020
Q4 | $2.8M | Sell |
391,656
-4,987
| -1% | -$47.9K | ﹤0.01% | 2899 |
|
|
2020
Q3 | $4.23M | Sell |
396,643
-8,361
| -2% | -$98.1K | ﹤0.01% | 2494 |
|
|
2020
Q2 | $5.11M | Buy |
405,004
+8,688
| +2% | +$101K | ﹤0.01% | 2331 |
|
|
2020
Q1 | $3.63M | Buy |
396,316
+12,641
| +3% | +$145K | ﹤0.01% | 2336 |
|
|
2019
Q4 | $5.35M | Buy |
383,675
+3,227
| +0.8% | +$46.9K | ﹤0.01% | 2413 |
|
|
2019
Q3 | $6.55M | Buy |
380,448
+11,219
| +3% | +$236K | ﹤0.01% | 2219 |
|
|
2019
Q2 | $10.1M | Buy |
369,229
+52,426
| +17% | +$1.2M | ﹤0.01% | 1951 |
|
|
2019
Q1 | $6.06M | Buy |
316,803
+29,539
| +10% | +$385K | ﹤0.01% | 2219 |
|
|
2018
Q4 | $2.7M | Buy |
287,264
+53,888
| +23% | +$692K | ﹤0.01% | 2590 |
|
|
2018
Q3 | $4.42M | Buy |
233,376
+152
| +0.1% | +$2.92K | ﹤0.01% | 2432 |
|
|
2018
Q2 | $4.56M | Buy |
233,224
+45,642
| +24% | +$902K | ﹤0.01% | 2378 |
|
|
2018
Q1 | $3.52M | Buy |
187,582
+14,909
| +9% | +$322K | ﹤0.01% | 2460 |
|
|
2017
Q4 | $2.87M | Buy |
172,673
+31,248
| +22% | +$536K | ﹤0.01% | 2551 |
|
|
2017
Q3 | $2.91M | Buy |
141,425
+73,265
| +107% | +$827K | ﹤0.01% | 2528 |
|
|
2017
Q2 | $610K | Buy |
68,160
+5,675
| +9% | +$57.1K | ﹤0.01% | 3291 |
|
|
2017
Q1 | $827K | Buy |
62,485
+4,516
| +8% | +$54.8K | ﹤0.01% | 3114 |
|
|
2016
Q4 | $738K | Buy |
57,969
+2,584
| +5% | +$33.2K | ﹤0.01% | 3127 |
|
|
2016
Q3 | $665K | Buy |
55,385
+1,953
| +4% | +$26.4K | ﹤0.01% | 3138 |
|
|
2016
Q2 | $587K | Buy |
53,432
+960
| +2% | +$11.7K | ﹤0.01% | 3154 |
|
|
2016
Q1 | $458 | Buy |
52,472
+8,488
| +19% | +$96.2K | ﹤0.01% | 3279 |
|
|
2015
Q4 | $963K | Buy |
+43,984
| New | +$1.01M | ﹤0.01% | 2928 |
|
Other funds holding VYGR
AC
EAM
Geode Capital Management's VYGR Position: Q2 2026 in Review
Geode Capital Management increased its Voyager Therapeutics (VYGR) stake by 27% in Q2 2026, buying an estimated $1.06M and bringing the position to 1,330,492 shares worth $4.66M. The position accounts for ﹤0.01% of the portfolio, ranked #2957.
Geode Capital Management first reported a position in VYGR in Q4 2015 and has held it in 43 quarters since. The position peaked at $10.1M in Q2 2019. 128 funds tracked by Wall St. Rank hold VYGR as of Q2 2026.
- Geode Capital Management held 1,330,492 shares of Voyager Therapeutics worth $4.66M as of Q2 2026.
- Geode Capital Management bought 280,514 Voyager Therapeutics shares in Q2 2026, an estimated $1.06M.
- Voyager Therapeutics made up ﹤0.01% of Geode Capital Management's portfolio in Q2 2026, its #2957 holding.
- Geode Capital Management first reported a position in Voyager Therapeutics in Q4 2015 and has held it in 43 quarters since.
- Geode Capital Management's Voyager Therapeutics position peaked at $10.1M in Q2 2019.
- 128 funds tracked by Wall St. Rank held Voyager Therapeutics as of Q2 2026.
Based on Geode Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.